Denosumab is a fully human monoclonal antibody belonging to the immunoglobulin G2 (IgG2) subclass, designed to specifically bind and neutralize the receptor activator of nuclear factor kappa-B ligand (RANKL). Structurally, Denosumab is a glycoprotein with a molecular weight of approximately 147 kilodaltons (kDa). It comprises two identical heavy chains and two identical light chains linked by disulfide bonds in the classic Y-shaped configuration characteristic of immunoglobulins. The molecule is produced in mammalian expression systems, typically Chinese Hamster Ovary (CHO) cells, which ensure proper folding, assembly, and human-like glycosylation essential for its stability and function.
The variable domains of Denosumab’s heavy (VH) and light (VL) chains contain complementarity-determining regions (CDRs) that confer high specificity for human RANKL, a trimeric cytokine belonging to the tumor necrosis factor (TNF) superfamily. These CDRs form a precise antigen-binding surface that engages RANKL via a network of hydrogen bonds and hydrophobic interactions with sub-nanomolar affinity. By binding directly to RANKL, Denosumab prevents it from interacting with its cognate receptor, RANK, located on the surface of osteoclast precursors and other myeloid-lineage cells. This blockade disrupts the RANK-RANKL signaling axis, which is a key regulator of cellular processes such as differentiation, activation, and survival of osteoclasts in experimental model systems.
The Fc (fragment crystallizable) region of Denosumab, derived from the IgG2 isotype, contributes to structural integrity and extended serum half-life through interactions with neonatal Fc receptors (FcRn). The IgG2 Fc structure, compared with IgG1, exhibits reduced effector function, minimizing unwanted complement activation or antibody-dependent cytotoxic responses.
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.
Have a product or application question? Consult our FAQs or contact us.
